Littlejohns Peter, Garner Sarah, Doyle Nick, Macbeth Fergus, Barnett David, Longson Carole
National Institute for Health and Clinical Excellence, London, UK.
Lancet Oncol. 2009 Apr;10(4):417-24. doi: 10.1016/S1470-2045(09)70077-4.
The National Institute for Health and Clinical Excellence (NICE) will have existed for 10 years on April 1, 2009. Over the past decade, the institute's methodological approach to the development of guidance and assessment of the value of health-care interventions has received international interest and acclaim. Furthermore, individual decisions, in particular those made on new cancer drugs, have generated enormous controversy. An early example was the appraisal of irinotecan and oxaliplatin for colorectal cancer in 2002. In 2003, NICE described the rationale behind its decision making. The 10th anniversary of the institute provides an opportunity to review some of the key issues affecting cancer appraisals and to explain the development of other NICE guidance programmes relevant to the provision of cancer services.
到2009年4月1日，英国国家卫生与临床优化研究所（NICE）将迎来成立10周年。在过去十年里，该研究所制定指南以及评估医疗保健干预措施价值的方法受到了国际关注并赢得赞誉。此外，个别决策，尤其是那些关于新型抗癌药物的决策，引发了巨大争议。一个早期的例子是2002年对伊立替康和奥沙利铂用于结直肠癌治疗的评估。2003年，NICE阐述了其决策背后的基本原理。该研究所成立10周年之际，有机会回顾一些影响癌症评估的关键问题，并解释NICE其他与癌症服务提供相关的指南项目的发展情况。
